These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 413639)

  • 21. Safety of meningococcal polysaccharide vaccine serogroup "A" (Pilot Study).
    Bahl MR
    Med J Zambia; 1975 Dec-1976 Jan; 9(6):166. PubMed ID: 818845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
    MenAfriCar consortium
    J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
    Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N;
    Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method].
    Ma Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Apr; 12(2):69-71. PubMed ID: 2065343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL; Gay NJ; Edmunds WJ
    Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003.
    Mueller JE; Yaro S; Traore Y; Sangare L; Tarnagda Z; Njanpop-Lafourcade BM; Borrow R; Gessner BD
    J Infect Dis; 2006 Mar; 193(6):812-20. PubMed ID: 16479516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningococcal carriage and vaccination in army recruits in Italy.
    Di Martino M; Calì G; Astorre P; Usai GC; Ferrari R; Stroffolini T
    Boll Ist Sieroter Milan; 1990; 69(1):357-9. PubMed ID: 2129323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
    Magdzik W
    Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Controlled tests of anti-meningococcal polysaccharide A vaccine in the African Sahel area (Upper Volta and Mali) ].
    Saliou P; Stoeckel P; Lafaye A; Rey JL; Renaudet J
    Dev Biol Stand; 1978; 41():97-108. PubMed ID: 572789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
    Guerin PJ; Naess LM; Fogg C; Rosenqvist E; Pinoges L; Bajunirwe F; Nabasumba C; Borrow R; Frøholm LO; Ghabri S; Batwala V; Twesigye R; Aaberge IS; Røttingen JA; Piola P; Caugant DA
    PLoS Negl Trop Dis; 2008; 2(12):e342. PubMed ID: 19048025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control of meningococcal meningitis with meningococcal vaccines.
    Artenstein MS
    Yale J Biol Med; 1975 Jul; 48(3):197-200. PubMed ID: 808913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.
    Mueller JE; Borrow R; Gessner BD
    Expert Rev Vaccines; 2006 Jun; 5(3):319-36. PubMed ID: 16827617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of SP-RIA in the antibody surveillance and serologic diagnosis of epidemic cerebrospinal meningitis].
    Chen X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Dec; 14(6):366-70. PubMed ID: 8156584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].
    Chippaux JP; Debois H; Saliou P
    Bull Soc Pathol Exot; 2002 Mar; 95(1):37-44. PubMed ID: 12012963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum opsonins to serogroup B meningococci after disease and vaccination.
    Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
    NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates.
    Sivonen A
    J Infect; 1981 Sep; 3(3):266-72. PubMed ID: 6821094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.